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Eribulin monotherapy improved 
survivals in patients with ER-positive 
HER2-negative metastatic breast cancer in the 
real world: a single institutional review
Junichiro Watanabe*
Abstract 
Despite being routinely prescribed worldwide for several years, data regarding the safety, efficacy, and survival benefit 
of eribulin in clinical settings for the treatment of metastatic breast cancer (MBC) are limited. This retrospective obser-
vational study investigated the survival benefit of eribulin compared with conventional chemotherapy regimens in 
Japanese women with MBC. Women with estrogen receptor (ER)-positive human epidermal growth factor receptor 2 
(HER2)-negative (ER+/HER2−) MBC, including unresectable locally advanced breast cancer, treated at a single institu-
tion were included in this study. The primary efficacy measure assessed overall survival (OS), and safety was evaluated 
as the number of grade 3 and 4 adverse events. Of the 293 patients analyzed, 66 received eribulin (eribulin arm) and 
227 received conventional chemotherapeutic agents excluding eribulin (noneribulin arm). The median OS from MBC 
diagnosis in the eribulin arm was 72.1 months (95 % CI 13.3–168.3) compared with 43.3 months (95 % CI 9.1–202.0) 
in the noneribulin arm [hazard ratio (HR): 0.67, 95 % CI 0.47–0.96; P = 0.025]. No significant differences were noted 
in OS between eribulin used as a first-/second-line or third-/>third-line treatment for MBC. No patient discontinued 
eribulin therapy due to AEs. In the eribulin arm, grade 4 neutropenia and grade 3 febrile neutropenia were observed 
in 8 (12.1 %) and 4 (6.1 %) patients, respectively. Eribulin therapy has a survival benefit in Japanese women with ER+/
HER2− MBC in routine clinical practice, with no unexpected grade 3/4 AEs. Interestingly, eribulin might be beneficial 
as any line therapy for ER+/HER2− MBC.
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Background
The treatment of metastatic breast cancer (MBC) 
remains a challenge, with approximately 6–10 % of new 
breast cancer cases being initially diagnosed as stage IV 
or metastatic in nature (Cardoso et  al. 2011). The cur-
rent therapies generally focus on symptomatic control 
and prolonging survival. Despite the development of 
novel treatment options, the improvement of long-
term survival in women with MBC still remains a chal-
lenge. The 5-year relative survival is reportedly as low as 
24.3  % for patients with distant metastases (Howlader 
et al. 2013), warranting effective treatment options with 
an increased survival benefit. Although systemic neo-
adjuvant/adjuvant chemotherapy may reduce mortality 
risks in those with breast cancer (Berry et al. 2005), the 
choice of chemotherapy regimen might affect long-term 
outcomes. Anthracycline- and taxane-based regimens 
remain the standard chemotherapy options for neo-adju-
vant/adjuvant and/or first-line treatment for MBC; how-
ever, disease progression is often attributed to primary or 
acquired resistance to these regimens. Subsequently, few 
therapeutic options are available for patients with anthra-
cycline- and taxane-resistant or refractory MBC. Despite 
limited evidence, these active chemotherapies are listed 
as potential sequential therapies in late-line treatment 
(Cardoso et  al. 2014; National Comprehensive Cancer 
Open Access
*Correspondence:  j.watanabe@scchr.jp 
Breast Oncology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, 
Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan
Page 2 of 6Watanabe  SpringerPlus  (2015) 4:625 
Network. NCCN clinical practice guidelines in oncology 
breast cancer, version 2 2015).
Recently, eribulin, a nontaxane microtubule dynamics 
inhibitor belonging to the halichondrin class of antineo-
plastic agents, has shown anticancer activity in women 
with MBC. Three phase II studies have demonstrated 
that eribulin has potent anticancer activity with accept-
able tolerability (Aogi et al. 2012; Cortes et al. 2010; Vah-
dat et al. 2009). A phase III randomized study (study 305, 
NCT00388726 or EMBRACE) demonstrated a significant 
and clinically meaningful improvement in survival with 
eribulin compared with the physician’s choice of treat-
ment in women who were heavily pretreated with man-
ageable toxicity (Cortes et al. 2011). In another phase III 
randomized study (study 301), eribulin showed a favora-
ble improvement in overall survival (OS) compared with 
capecitabine; however, this improvement did not meet 
the predefined criteria for statistical significance (Kauf-
man et  al. 2015. In addition, a pooled analysis of both 
the aforementioned phase III studies demonstrated that 
eribulin-treated patients had a significantly prolonged 
OS compared with the controls. Moreover, the OS results 
for eribulin were favorable in all population subgroups 
(Twelves et al. 2014). Based on the results of these stud-
ies, eribulin has been approved in the United States and 
certain other countries for the treatment of MBC previ-
ously treated with at least two chemotherapeutic agents, 
including anthracycline- and taxane-based regimens. In 
Europe, eribulin has been approved for the treatment of 
MBC previously treated with at least one chemotherapy 
regimen. In Japan, on the other hand, eribulin has been 
approved for the treatment of patients with inoperable 
or recurrent breast cancer but not limited to those who 
have been previously treated with chemotherapy regi-
mens for MBC.A phase II study of eribulin in Japanese 
patients with locally advanced disease or MBC who were 
hormone receptor and HER2 positive as well as previ-
ously treated with an anthracycline and a taxane, eribulin 
demonstrated an OS of 11.1  months, respectively (Aogi 
et al. 2012).
Several retrospective and prospective studies have 
demonstrated the therapeutic benefits of eribulin (Aogi 
et  al. 2012; Cortes et  al. 2010; Vahdat et  al. 2009; Cor-
tes et al. 2011; Kaufman et al. 2015; Twelves et al. 2014; 
Gamucci et al. 2014; Poletti et al. 2014); however, extrap-
olation of these findings to real-world settings remains to 
be explored. Although eribulin has been clinically used 
as a treatment option in Japanese women diagnosed with 
MBC for over a year, evidence of its safety and efficacy 
in clinical settings is not extensively documented. More-
over, the survival benefit of eribulin over conventional 
chemotherapy is yet to be determined; thus, the present 
study was conducted to investigate the survival benefit of 
eribulin compared with conventional chemotherapy regi-




A total of 325 patients with ER+/HER2− MBC including 
LABC were assessed in this study. Of these, 293 patients 
(214 with metastatic and 79 with locally advanced dis-
ease) had been treated with at least one chemotherapy 
regimen recommended by the NCCN guidelines for the 
treatment of MBC (eribulin arm: 66 patients; noneribu-
lin arm: 227 patients). Baseline patient characteristics at 
diagnosis of MBC are presented in Table 1. The median 
age in both eribulin and noneribulin arms was 54.0 years 
(range 27–77 and 25–78 years, respectively). In the eribu-
lin arm, the median exposure to eribulin was 4.2 months, 
and the median relative dose intensity was 47.4  %. The 
median duration of eribulin treatment was 125  days, 
ranging from 2 to 454 days. All the patients had stage IV 
disease and an ECOG PS 0–2.
Efficacy outcomes
A total of 214 (73.0  %) patients died during the study 
period, of whom, 39 were from the eribulin arm and 175 
from the noneribulin arm. Kaplan–Meier survival curves 
for OS in the eribulin and noneribulin arms are shown 
in Fig.  1. The median OS from diagnosis of MBC was 
72.1  months (95  % CI 13.3–168.3) in the eribulin arm 
compared with 43.3  months (95  % CI 9.1–202.0) in the 
noneribulin arm; OS was significantly prolonged in the 
eribulin arm (HR: 0.67, 95 % CI 0.47–0.96; P = 0.025).
The influence of chemotherapy regimens on OS was 
analyzed using a Cox proportional hazards model, con-
trolling for each factor at a time. Based on the analyses, 
only eribulin monotherapy significantly prolonged the 
OS (HR: 0.55, 95 % CI 0.36–0.85; P = 0.01; Table 2). In 
contrast, patients who received an anthracycline-based 
regimen (HR: 1.35, 95  % CI 1.01–1.82; P  =  0.04) or a 
paclitaxel + gemcitabine combination regimen (HR: 2.79, 
95  % CI 1.34–5.79; P =  0.01) showed significantly poor 
outcomes (Table 2).
Furthermore, among the patients who were treated 
with eribulin, the influences of clinical characteristics of 
the patients and specific treatments at initiation of eribu-
lin on OS were analyzed. Prior use of an anthracycline-
based regimen and duration of treatment with eribulin 
were statistically significant clinical variables associated 
with prolonged OS in MBC (HR: 0.36, 95 % CI 0.11–0.83; 
P  =  0.02 and HR: 0.45, 95  % CI 0.21–0.94; P  =  0.032; 
Table  3). No significant differences were observed in 
OS with the use of eribulin as first-, second-, third-, or 
beyond third-line treatment for MBC.
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Safety outcomes
No patient discontinued eribulin therapy due to adverse 
events. No grade 3 or 4 neuropathy was documented. 
Grade 4 neutropenia was observed in 8 (12.1 %) patients, 
and grade 3 febrile neutropenia was observed in 4 (6.1 %) 
patients. None of these events was related to eribulin 
according to the investigator. No other grade 3/4 hema-
tological or non-hematological toxicity was documented.
Discussion
This retrospective observational study investigated the 
survival benefit of eribulin compared with other conven-
tional chemotherapy regimens in Japanese women with 
ER+/HER2− MBC. The present analyses revealed a pro-
longed OS in patients treated with eribulin than in those 
treated with other chemotherapy regimens. In addi-
tion, these analyses showed that eribulin monotherapy 
Table 1 Baseline demographics and clinical characteristics at diagnosis of metastatic breast cancer
CNS central nervous system, EBC early breast cancer, MBC metastatic breast cancer
 Variables Overall Eribulin Noneribulin P value Fisher’s 
exact test
(N = 293) (N = 66) (N = 227)
Median age, years (range) 54.0 (25–78) 55.0 (27–77) 54.0 (25–78)
Diagnosis, n (%)
 Metastatic 214 (73.0) 44 (66.7) 170 (74.9) 0.21
 Locally advanced 79 (27.0) 22 (33.3) 57 (25.1)
Sites of metastases, n (%)
 Lung 71 (24.2) 16 (24.2) 55 (24.2) 1.00
 Liver 58 (19.8) 20 (30.3) 38 (16.7) 0.02*
 Bone 155 (52.9) 35 (53.0) 120 (52.9) 1.00
 CNS 14 (4.8) 3 (0.5) 11 (4.8) 1.00
 Soft tissue 185 (63.2) 44 (66.7) 141 (62.1) 0.56
Treatment regimens, n (%)
 Anthracycline-based regimen for EBC 79 (27.0) 22 (33.3) 57 (25.1)
 Anthracycline-based regimen for MBC 135 (46.1) 26 (39.4) 109 (48.0)
 Taxane-based regimen for EBC 39 (13.3) 18 (27.3) 21 (9.3)
 Taxane-based regimen for MBC 228 (77.8) 53 (80.3) 175 (77.1)
 Eribulin as first-/second-line for MBC 31 (47.0) 31 (47.0) –
 Taxane-based regimen prior to eribulin 40 (13.7) 40 (60.6) –
Fig. 1 Kaplan–Meier estimates of overall survival. The primary efficacy measure in the present study assessed overall survival, which was calculated 
as the time from diagnosis of metastatic breast cancer until death from any cause. HR denotes hazard ratio for the eribulin arm as compared with 
the noneribulin arm
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provided a survival benefit with an efficacy that is inde-
pendent of its use as a front- or late-line therapy. More-
over, no patient discontinued eribulin therapy due to 
adverse events.
The median OS for eribulin-treated patients was 
72.1 months, suggesting that the median OS recorded in 
this study is significant, particularly in patients who had 
been treated with eribulin for more than 125 days. Cur-
rently, no treatment standard has been established for 
patients with MBC requiring third- or fourth-line ther-
apy. The results of the EMBRACE study (Cortes et  al. 
2011) and the pooled analysis of two phase III studies 
(EMBRACE and study 301) (Twelves et al. 2014) suggest 
that eribulin could prolong survival in patients with late-
stage MBC, particularly in those who have been heavily 
pretreated. In the present study, eribulin demonstrated 
a significant survival benefit in patients treated with an 
anthracycline-based regimen for MBC; thus, eribulin 
may be beneficial for patients who did not respond to an 
anthracycline-based regimen. In addition, almost half of 
the eribulin-treated patients had received the drug as a 
third- or beyond third-line treatment, and the efficacy of 
eribulin in these patients was comparable to those who 
received eribulin as first- or second-line treatment. Taken 
together, eribulin might be beneficial not only as a late-
line but also as a front-line treatment for MBC. In certain 
countries, eribulin has been approved for the treatment 
of patients with MBC who were previously treated with 
at least two chemotherapy regimens, including anthra-
cycline- and taxane-based regimens; however, in Japan, 
eribulin has been approved for patients with inoperable 
or recurrent breast cancer, irrespective of their previ-
ous treatment history. The present study supports the 
indication of eribulin use in Japan and demonstrates its 
potential as a therapeutic option for patients with MBC, 
regardless of the treatment line.
Since HER2 has been shown to play a vital role in the 
development and progression of certain types of breast 
cancer, several novel anti-HER2 therapeutic agents, 
including trastuzumab, lapatinib, pertuzumab, and tras-
tuzumab emtansine have been developed. Based on the 
Surveillance, Epidemiology, and End Results registries in 
the United States, 72.7 % patients with MBC were found 
to be hormone receptor positive (HR+)/HER2−, and 
12.2  % were triple-negative (HR−/HER2−) (Howlader 
et  al. 2014); however, the aforementioned novel anti-
HER2 therapeutic agents may not be suitable for a major-
ity of these patients. Compared with diseases that exhibit 
an HER2-positive profile, those with an HER2-negative 
profile are heterogeneous, and biomarkers for such dis-
eases have not yet been established. Thus, additional 
Table 2 Administered agents/regimens and hazard ratio for overall survival
CI confidence interval, HR hazard ratio
Agents/regimens No. of  
patients
No. of events,  
n (%)
HR 95 % CI P value
Eribulin monotherapy 66 39 (59.1) 0.55 0.36–0.85 0.01*
Anthracycline-based regimen 136 120 (88.2) 1.35 1.01–1.82 0.04*
Paclitaxel monotherapy 138 103 (74.6) 1.14 0.85–1.52 0.38
Docetaxel monotherapy 79 72 (91.1) 1.30 0.95–1.79 0.10
Capecitabine monotherapy 120 100 (83.3) 0.89 0.66–1.20 0.43
Gemcitabine monotherapy 12 12 (83.3) 0.55 0.27–1.10 0.09
Vinorelbine monotherapy 37 37 (100.0) 1.15 0.76–1.73 0.51
Paclitaxel + bevacizumab 52 52 (57.7) 1.51 0.93–2.48 0.10
Docetaxel + capecitabine 30 30 (96.7) 1.13 0.74–1.73 0.57
Paclitaxel + gemcitabine 10 10 (100.0) 2.79 1.34–5.79 0.01*
Table 3 Prognostic factors for overall survival in the eribu-
lin arm
CI confidence interval, CNS central nervous system, EBC early breast cancer, HR 
hazard ratio, MBC metastatic breast cancer
Variables n HR 95 % CI P value
Lung metastasis 27 0.90 0.42–1.95 0.79
Liver metastasis 36 1.25 0.56–2.78 0.59
Bone metastasis 43 1.42 0.58–3.50 0.44
CNS metastasis 9 1.36 0.44–4.17 0.59
Other metastasis 47 0.46 0.20–1.02 0.06
Anthracycline-based regimen for EBC 21 0.51 0.15–1.73 0.28
Anthracycline-based regimen for MBC 24 0.36 0.11–0.83 0.02*
Taxane-based regimen for EBC 13 0.48 0.08–2.77 0.41
Taxane-based regimen for MBC 41 0.66 0.22–1.96 0.45
Eribulin as first-/second-line for MBC 31 0.90 0.37–2.20 0.82
Taxane-based regimen prior to eribulin 28 1.41 0.63–3.14 0.40
Duration of eribulin treatment >median 
(125 days)
33 0.45 0.21–0.94 0.03*
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investigations on the benefits of treatment independently 
with biomarkers are warranted. According to the results 
of the present study, the survival benefit of eribulin was 
observed among the patients with ER+/HER2− MBC. A 
subgroup analysis of the previous pooled analysis showed 
that eribulin has a tendency to prolong OS which was not 
statistically significantly in the subpopulation with ER+/
HER2− MBC (HR: 0.86, 95  % CI 0.74–1.01; P  =  0.06) 
(Twelves et al. 2014). These study results support the use 
of eribulin as a potential therapeutic option for the treat-
ment of ER+/HER2− MBC; however, additional inves-
tigations on the benefits of eribulin in such patients are 
warranted.
In the present study, eribulin had an acceptable safety 
profile. Grade 3 and 4 neutropenia were observed in 6.1 
and 12.1 % patients, respectively, and no other grade 3/4 
hematological or non-hematological toxicity was docu-
mented. Notably, grade 3/4 peripheral neuropathy, the 
most common adverse event leading to discontinuation 
of eribulin therapy in EMBRACE, was not observed in 
the present study. In addition, no patient discontinued 
eribulin therapy due to adverse events. Based on the 
low incidence of adverse events and no treatment dis-
continuation, the safety profile of eribulin in the present 
study may be considered more acceptable than that in 
previously reported phase II/III studies (Aogi et al. 2012; 
Cortes et al. 2010; Vahdat et al. 2009; Cortes et al. 2011; 
Kaufman et al. 2015; Twelves et al. 2014). The median rel-
ative dose intensity of eribulin was 47.4 %, and the dose 
was modified to prevent the occurrence of unwarranted 
toxicity at the physician’s discretion. Hence, the dose of 
eribulin may be modified based on an individual patient’s 
needs to minimize its toxicity and maximize benefits.
Unlike randomized clinical trials that have strict 
inclusion criteria, the retrospective nature of this 
study allowed the inclusion of a variety of patients. 
Since patient groups are usually more heterogeneous, 
these findings may provide a realistic picture of what is 
observed in routine clinical practice as the strength of the 
study. However, the present study has a few limitations. 
This was a retrospective observational study, and the two 
arms were compared without randomization; thus, inter-
pretation and generalization of the findings should be 
conducted with caution. The sample size was relatively 
small, and this was an exploratory study and not a con-
firmatory one. In addition, subjective bias may have had 
some impact on the results.
Conclusion
In summary, as with phase II/III studies, the present 
study which retrospectively investigated the efficacy 
and safety of eribulin in Japanese women with ER+/
HER2− MBC in routine clinical practice demonstrated 
a significant survival benefit of eribulin in such patients, 
with a relatively lower dose intensity and no unexpected 
grade 3 and 4 adverse events. The survival benefit of 
eribulin was regardless of the organs involved, previous 
treatment regimens, or line of treatment. Eribulin might 
be beneficial as any line treatment for ER+/HER2− 
MBC; however, further validation of the current findings 
should be performed in a larger study.
Methods
Patients
This retrospective observational study included Japa-
nese women with MBC, including unresectable locally 
advanced breast cancer (LABC), who were treated at 
the Shizuoka Cancer Center Hospital (Shizuoka, Japan) 
between October 1, 2002, and November 30, 2014. 
Women diagnosed with ER-positive HER2-negative 
(ER+/HER2−) MBC and treated with at least one chem-
otherapy regimen were included. Eribulin was adminis-
tered based on the approved dosage and administration 
practice in Japan, via drip intravenous infusion at a maxi-
mum flow of 1.4 mg/m2 on days 1 and 8 every 3 weeks. 
Other conventional chemotherapeutic agents were also 
administered based on the approved dosage and admin-
istration practices in Japan. Dose modifications such as 
dose reduction or dose omission on day 8 were permit-
ted based on the physician’s discretion. Treatment could 
be discontinued based on the physician’s decision (e.g., 
disease progression, unacceptable toxicity, or worsening 
health status) or the patient’s request to do so.
The study design was approved by the Clinical 
Research Ethics Committee and the study was conducted 
in accordance with the latest Ethical Guidelines for Medi-
cal and Health Research Involving Human Subjects and 
the local regulations in Japan.
Outcome assessments
Demographics and baseline characteristics of all the 
patients, including age, HER2 and ER status, treatment 
history, and sites of metastases were collected upon diag-
nosis of MBC. In addition, the median treatment dura-
tion and dose intensity of eribulin were assessed. The 
primary efficacy measure assessed OS, which was calcu-
lated as the time from the diagnosis of MBC until death 
from any cause. To evaluate safety, grade 4 neutropenia, 
grade 3 febrile neutropenia, and grade 3/4 hematologi-
cal or non-hematological toxicity were assessed only in 
patients who received eribulin. Adverse events were 
recorded and graded according to the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (version 3.0, Japanese version).
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Statistical analysis
The final data cut-off date was November 30, 2014. OS 
curves for patients who received eribulin (eribulin arm) 
and conventional chemotherapy excluding eribulin (non-
eribulin arm) were estimated using the Kaplan–Meier 
method, and both arms were compared using the log-
rank test. Hazard ratios (HRs) and 95 % confidence inter-
vals (CIs) were estimated using the Cox proportional 
hazards model to investigate the influence of chemother-
apy regimens on OS. Moreover, subgroup analyses were 
performed using the Cox proportional hazards model 
to identify clinically relevant interactions between treat-
ment outcomes and prognostic factors including sites of 
metastases, previous treatments, duration of treatment, 
and the time of initiation of eribulin. For multivariate 
analyses, patients who were treated with agents not rec-
ommended according to the latest National Compre-
hensive Cancer Network (NCCN) guidelines (National 
Comprehensive Cancer Network. NCCN clinical prac-
tice guidelines in oncology breast cancer, version 2 2015) 
(e.g., TS-1 monotherapy and capecitabine +  cyclophos-
phamide combination therapy) were excluded owing to 
the small number of patients. All statistical analyses were 
two-sided, and P values <0.05 were considered statisti-
cally significant.
Abbreviations
ER+/HER2−: estrogen receptor (ER)-positive human epidermal growth factor 
receptor 2 (HER2)-negative; HR: hazard ratio; LABC: locally advanced breast 
cancer; MBC: metastatic breast cancer; OS: overall survival.
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